Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 25 09 2018
accepted: 26 11 2018
revised: 14 11 2018
pubmed: 6 12 2018
medline: 29 5 2019
entrez: 6 12 2018
Statut: ppublish

Résumé

Cognitive impairment (CI) affects approximately one-third of the patients with early multiple sclerosis (MS) and clinically isolated syndrome (CIS). Little is known about factors predicting CI and progression after initial diagnosis. Neuropsychological screening data from baseline and 1-year follow-up of a prospective multicenter cohort study (NationMS) involving 1123 patients with newly diagnosed MS or CIS were analyzed. Employing linear multilevel models, we investigated whether demographic, clinical and conventional MRI markers at baseline were predictive for CI and longitudinal cognitive changes. At baseline, 22% of patients had CI (impairment in ≥2 cognitive domains) with highest frequencies and severity in processing speed and executive functions. Demographics (fewer years of academic education, higher age, male sex), clinical (EDSS, depressive symptoms) but no conventional MRI characteristics were linked to baseline CI. At follow-up, only 14% of patients showed CI suggesting effects of retesting. Neither baseline characteristics nor initiation of treatment between baseline and follow-up was able to predict cognitive changes within the follow-up period of 1 year. Identification of risk factors for short-term cognitive change in newly diagnosed MS or CIS is insufficient using only demographic, clinical and conventional MRI data. Change-sensitive, re-test reliable cognitive tests and more sophisticated predictors need to be employed in future clinical trials and cohort studies of early-stage MS to improve prediction.

Sections du résumé

BACKGROUND BACKGROUND
Cognitive impairment (CI) affects approximately one-third of the patients with early multiple sclerosis (MS) and clinically isolated syndrome (CIS). Little is known about factors predicting CI and progression after initial diagnosis.
METHODS METHODS
Neuropsychological screening data from baseline and 1-year follow-up of a prospective multicenter cohort study (NationMS) involving 1123 patients with newly diagnosed MS or CIS were analyzed. Employing linear multilevel models, we investigated whether demographic, clinical and conventional MRI markers at baseline were predictive for CI and longitudinal cognitive changes.
RESULTS RESULTS
At baseline, 22% of patients had CI (impairment in ≥2 cognitive domains) with highest frequencies and severity in processing speed and executive functions. Demographics (fewer years of academic education, higher age, male sex), clinical (EDSS, depressive symptoms) but no conventional MRI characteristics were linked to baseline CI. At follow-up, only 14% of patients showed CI suggesting effects of retesting. Neither baseline characteristics nor initiation of treatment between baseline and follow-up was able to predict cognitive changes within the follow-up period of 1 year.
CONCLUSIONS CONCLUSIONS
Identification of risk factors for short-term cognitive change in newly diagnosed MS or CIS is insufficient using only demographic, clinical and conventional MRI data. Change-sensitive, re-test reliable cognitive tests and more sophisticated predictors need to be employed in future clinical trials and cohort studies of early-stage MS to improve prediction.

Identifiants

pubmed: 30515631
doi: 10.1007/s00415-018-9142-y
pii: 10.1007/s00415-018-9142-y
pmc: PMC6373354
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

386-397

Subventions

Organisme : Bundesministerium für Forschung und Technologie
ID : 01GI0914
Organisme : Bundesministerium für Forschung und Technologie
ID : 01GI1601B
Organisme : Bundesministerium für Bildung und Forschung
ID : 01GI0916
Organisme : Bundesministerium für Bildung und Forschung
ID : 01GI1601G

Investigateurs

Seray Demir (S)
Christoph Schröder (C)
Lisa A Voithenleitner (LA)
Achim Berthele (A)
Sarah Haars (S)
Sandra Nischwitz (S)
Matthias J Knop (MJ)
Susanne Rothacher (S)
Jana Pöttgen (J)
Clemens Warnke (C)
Ralf A Linker (RA)
Ulf Ziemann (U)

Références

Brain. 1999 May;122 ( Pt 5):871-82
pubmed: 10355672
Clin Neuropsychol. 1999 Aug;13(3):283-92
pubmed: 10726600
Arch Neurol. 2004 Feb;61(2):226-30
pubmed: 14967771
Nervenarzt. 2004 Oct;75(10):984-90
pubmed: 15118827
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
J Neurol Sci. 2006 Jun 15;245(1-2):41-6
pubmed: 16643953
Mult Scler. 2007 Jan;13(1):124-7
pubmed: 17294621
Appl Neuropsychol. 2007;14(2):88-100
pubmed: 17523883
Neurology. 1991 May;41(5):692-6
pubmed: 1823781
J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):955-8
pubmed: 18339729
Mult Scler. 2009 Jul;15(7):779-88
pubmed: 19542262
Mult Scler. 2010 Dec;16(12):1474-82
pubmed: 20729256
BMC Neurosci. 2010 Sep 16;11:118
pubmed: 20846444
J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1157-9
pubmed: 20971755
Neurology. 2011 Mar 29;76(13):1161-7
pubmed: 21444901
Nat Rev Neurol. 2011 May 10;7(6):332-42
pubmed: 21556031
Mult Scler. 2012 Jun;18(6):891-8
pubmed: 22190573
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2012 Nov;19(6):759-68
pubmed: 22670852
PLoS One. 2013 Jul 29;8(7):e69820
pubmed: 23922813
Mult Scler. 2014 Apr;20(4):481-8
pubmed: 24019305
J Neurol. 2014 Sep;261(9):1735-44
pubmed: 24952618
BMC Neurol. 2015 Mar 22;15:40
pubmed: 25886168
Clin Neuropsychol. 2016;30(1):17-50
pubmed: 26734714
Alzheimers Dement (Amst). 2015 Mar 29;1(1):103-11
pubmed: 27239497
Mult Scler. 2017 Aug;23(9):1258-1267
pubmed: 27738090
Mult Scler Relat Disord. 2016 Nov;10:116-122
pubmed: 27919477
J Neurol. 2017 Mar;264(3):482-493
pubmed: 28028623
Mult Scler. 2017 Apr;23(5):721-733
pubmed: 28206827
Mult Scler. 2018 Feb;24(2):186-195
pubmed: 28273771
Neurosci Biobehav Rev. 2017 Dec;83:568-578
pubmed: 28890199
Neurology. 2018 Feb 6;90(6):278-288
pubmed: 29343470
Ann Clin Transl Neurol. 2017 Dec 15;5(1):81-91
pubmed: 29376094
Front Neurol. 2018 Jan 24;8:727
pubmed: 29416523
Neurol Neuroimmunol Neuroinflamm. 2018 Mar 01;5(3):e446
pubmed: 29511705
Mult Scler Relat Disord. 2018 May;22:41-48
pubmed: 29554549
Mult Scler Relat Disord. 2018 May;22:70-76
pubmed: 29605801
Brain. 1997 Nov;120 ( Pt 11):2059-69
pubmed: 9397021

Auteurs

Andreas Johnen (A)

Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany. a.johnen@uni-muenster.de.

Paul-Christian Bürkner (PC)

Department of Statistics, Faculty of Psychology, Westfälische-Wilhelms-University, Münster, Germany.

Nils C Landmeyer (NC)

Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

Björn Ambrosius (B)

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Pasquale Calabrese (P)

Department of Neuropsychology and Behavioral Neurology, University of Basel, Basel, Switzerland.

Jeremias Motte (J)

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Nicole Hessler (N)

Institute of Medical Biometry and Statistics, University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Gisela Antony (G)

Central Information Office (CIO), Philipps-University Marburg, Marburg, Germany.

Inke R König (IR)

Institute of Medical Biometry and Statistics, University of Lübeck, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Luisa Klotz (L)

Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

Muna-Miriam Hoshi (MM)

Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Lilian Aly (L)

Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Sergiu Groppa (S)

Department of Neurology and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Felix Luessi (F)

Department of Neurology and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Friedemann Paul (F)

NeuroCure Clinical Research Center and Experimental and Clinical Research Center, Charité, University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.

Björn Tackenberg (B)

Department of Neurology, Philipps-University Marburg, Marburg, Germany.

Florian Then Bergh (FT)

Department of Neurology, University of Leipzig, Leipzig, Germany.

Tania Kümpfel (T)

Institute of Clinical Neuroimmunology, Ludwig Maximilian University of Munich, Munich, Germany.

Hayrettin Tumani (H)

Department of Neurology, University of Ulm, Ulm, Germany.
Clinic of Neurology Dietenbronn, Schwendi, Germany.

Martin Stangel (M)

Department of Neurology, Hannover Medical School, Hannover, Germany.

Frank Weber (F)

Neurology, Max-Planck-Institute of Psychiatry, Munich, Germany.
Neurological Clinic, Sana Kliniken des Landkreises Cham, Cham, Germany.

Antonios Bayas (A)

Department of Neurology, Klinikum Augsburg, Augsburg, Germany.

Brigitte Wildemann (B)

Department of Neurology, University of Heidelberg, Heidelberg, Germany.

Christoph Heesen (C)

Institut für Neuroimmunologie und Multiple Sklerose, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

Uwe K Zettl (UK)

Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.

Frauke Zipp (F)

Department of Neurology and Focus Program Translational Neuroscience (FTN), Rhine Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Bernhard Hemmer (B)

Department of Neurology, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Sven G Meuth (SG)

Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

Ralf Gold (R)

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Heinz Wiendl (H)

Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

Anke Salmen (A)

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Department of Neurology, Inselspital Bern, Bern University Hospital and University of Bern, Bern, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH